ACRS Forecast and Technical Stock Analysis

Sell candidate since 2019-06-20 Loss -60.12%

Aclaris Therapeutics fell by -5.24% in the last day ( Friday, 19th Jul 2019 ) from $2.10 to $1.99 and has now fallen 5 days in a row. During day the stock fluctuated 6.06% from a day low at $1.98 to a day high of $2.10. The price has fallen in 8 of the last 10 days and is down by -15.68% for this period. Volume has increased in the last day by 145 672 shares, but on falling prices. This may be an early warning and the risk will be increased slightly for the next couple of days. In total, 425 967 shares bought and sold for approximately $847 674.00.

Quick summary:

  • 30 day high of the ACRS stock price was $5.37 and low was $1.93.
  • 90 day high was $7.15 and low was $1.93.
  • 52 week high for the Aclaris Therapeutics - $20.75 and low - $1.93.
Top Trending Stocks


Aclaris Therapeutics lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -58.56% during the next 3 months and, with 90% probability hold a price between $0.39 and $1.43 at the end of this period.

Top Golden Star Stocks


There are few to none technical positive signals at the moment. Aclaris Therapeutics holds sales signals from both short- and long-term moving averages. In addition, there is a general sales signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up there will be some resistance from the lines at $2.15 and $3.57. A break-up above any of these levels will issue buy signals. A sales signal was issued from a pivot top point on Wednesday July 03, 2019, which indicates further falls until a new bottom pivot has been found. Aclaris Therapeutics gained volume on the last day, but on falling prices. In technical terms this is called divergence and may be an early warning. In some cases, increasing volume on falling prices may be considered positive, but that is mainly in typical "sell-off's".

Relative Strength Index (RSI)

RSImin/max Values: [ 20 - 75 ]

RSI14 is 43 and the stock is currently not being overbought or oversold

* Stockinvest.us uses dynamical calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.

Support & Resistance

There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.

Price: $1.99 Resistance: $2.13


This stock may move much during a day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.12 between high and low, or 6.06%. For the last week, the stock has had a daily average volatility of 5.84%.

Our recommended stoploss: We hold a sell evaluation for this stock. No stop-loss set.

5.84 %

Average volatility

Overall risk:

Very Low Low Medium High Very High

Strong Sell Candidate Downgraded


Aclaris Therapeutics holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our recommendation for this stock since last evaluation from a Sell Candidate to a Strong Sell Candidate.

Stronger Sell Today ACRS ranks #5448 as SELL CANDIDATE #5448 Weaker Sell

Will ACRS stock price go up or down on Mon, 22 Jul 2019?

Trading With Moving Average
As an investor, you always seek to understand what other... Full Article
Pivot Points
Pivot Points refer to points of significant change. As a... Full Article
Accumulated Volume - Support and Resistance
Volume is perhaps the best indicator of all and should... Full Article
Volume - The Indicator You Really Need to Know
Many new traders getting into the world of technical analysis... Full Article
We Give Back!
In 2016 StockInvest.us donated to NGO Goodwill projects to help purchase medical... Full Article
Better Buy: Amazon vs. Facebook
Amazon's stock slipped 21% over the past six months, as... Full Article

Proudly made at